Hong Kong Diversified Financial Stock News

AIA Group Limited recently reported a record 25% rise in its third-quarter 2025 value of new business, with double-digit growth led by Hong Kong, Mainland China, ASEAN, and India. This result was driven by a record agency value of new business and an 18% increase in recruitment, reflecting the company's strong distribution capabilities in Asian markets. We'll examine how AIA Group's record growth in new business value influences its investment outlook and long-term earnings narrative. These...

Innovent Biologics recently reported third quarter 2025 product revenue exceeding RMB 3.3 billion, achieving around 40% year-on-year growth driven by both oncology and newly launched biomedicine therapies, including mazdutide and SINTBILO®. The company also announced positive Phase 3 results for mazdutide, showing it surpassed semaglutide in both glycemic and weight reduction outcomes for Chinese patients with type 2 diabetes and obesity, highlighting a potential new-generation treatment...

Weichai Power (SEHK:2338) reported another year of earnings growth, with net profit margins improving to 5.3% from 5.1% and annual earnings rising by 8.8%, outpacing its five-year average of 5.6% a year. Looking ahead, forecasts point to annual earnings growth of 10.92% and revenue gains of 5.8% per year. Trading at a price-to-earnings ratio of 10.6x, which stands below both the peer average and industry levels, the stock offers investors a margin story supported by solid profitability...

CSPC Pharmaceutical Group (SEHK:1093) has just made headlines with two R&D milestones. Its JSKN003 therapy gained Breakthrough Therapy Designation for advanced colorectal cancer, and SYH2061 secured clearance for clinical trials in China. See our latest analysis for CSPC Pharmaceutical Group. After a stellar run earlier this year, CSPC Pharmaceutical Group’s share price recently cooled off, dropping 18.4% over the past month and 22.7% in the last 90 days. Still, its year-to-date share price...

Everest Medicines (SEHK:1952) has secured exclusive rights to develop and commercialize VIS-101, a promising bifunctional treatment for eye conditions like wet AMD, across Greater China and parts of Asia. This strategic move underscores the company’s ambitions in ophthalmology and signals potential growth ahead. See our latest analysis for Everest Medicines. Everest Medicines’ exclusive VIS-101 deal adds momentum to a year already marked by strong long-term performance. The company posted an...

Key Insights Significant insider control over VCREDIT Holdings implies vested interests in company growth 51% of the...

China Gingko Education Group Company Limited ( HKG:1851 ) shareholders would be excited to see that the share price has...

Key Insights The projected fair value for CMON is HK$0.044 based on 2 Stage Free Cash Flow to Equity With HK$0.04 share...

Unfortunately for some shareholders, the Shandong Hi-Speed Holdings Group Limited ( HKG:412 ) share price has dived 54...

Key Insights Man Wah Holdings' significant insider ownership suggests inherent interests in company's expansion Man Li...

Following the solid earnings report from China National Building Material Company Limited ( HKG:3323 ), the market...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It is hard to get excited after looking at China Medical System Holdings' (HKG:867) recent performance, when its stock...

Despite the fact that China Dredging Environment Protection Holdings Limited (HKG:871) stock rose 11% last week...

Yoho Group Holdings Limited ( HKG:2347 ) shareholders won't be pleased to see that the share price has had a very rough...

Most readers would already be aware that Global New Material International Holdings' (HKG:6616) stock increased...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

The Mingfa Group (International) Company Limited ( HKG:846 ) share price has fared very poorly over the last month...

Key Insights Hengan International Group's significant insider ownership suggests inherent interests in company's...

Key Insights The considerable ownership by public companies in Wynn Macau indicates that they collectively have a...

New World Development (SEHK:17) shares have seen some movement recently, prompting investors to keep an eye on how the stock is navigating current market dynamics. Its activity this month stands out as market watchers examine future prospects. See our latest analysis for New World Development. New World Development’s shares have been on a rollercoaster this year, with short-term gains giving way to recent losses. After a sharp 90-day share price return of 10.45% and a strong year-to-date...

Industrial and Commercial Bank of China (SEHK:1398) posted annual earnings growth of 2.6% over the last five years and is now forecast to grow earnings at 3.4% per year going forward. Revenue is projected to climb at 8.8% per year, slightly outpacing the wider Hong Kong market, with net profit margins holding at a healthy 51.6%. This is down from 54.2% last year, highlighting some pressure on profitability despite solid ongoing profits. Investors may note that ICBC's earnings growth is...

China Galaxy Securities (SEHK:6881) delivered standout results, with earnings soaring 76.9% over the past year, far outpacing its 5-year annual average of just 1.7%. Net profit margins reached 27.2%, beating last year’s 22.6%, and the share price at HK$11.18 trades below the estimated fair value of HK$12.84, helping the stock's valuation case. While earnings and revenue growth are expected to lag the broader Hong Kong market, ongoing profit gains and a competitive Price-to-Earnings Ratio...

JD Logistics (SEHK:2618) shares have edged up recently, with investors keeping an eye on the company’s performance as it navigates shifting demand in China’s logistics sector. The stock’s month return is down 3%. See our latest analysis for JD Logistics. While JD Logistics’ 1-day and 7-day share price returns have edged modestly higher, momentum has clearly faded compared to earlier in the year. The company now sits at a 1-year total shareholder return of -20.7%, which highlights the...